CD34 is a specific marker of mature murine mast cells

Experimental Hematology

Volumn 30, Issue 10, 2002, Pages 1211-1218

  Drew, Erin ^a   Merkens, Helen ^a   Chelliah, Shierley ^a   Doyonnas, Regis ^a   McNagny, Kelly M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CD34 ANTIGEN; CELL ANTIGEN; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL SURFACE; CONTROLLED STUDY; HEMATOPOIETIC CELL; IMMUNOFLUORESCENCE; MAST CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; PERITONEUM MAST CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ANIMALS; ANTIGENS, CD34; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC;

MURINAE;

EID: 0036792024     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00890-1     Document Type: Article

References (62)

1. Metcalf D. Cellular hematopoiesis in the twentieth century. Semin Hematol. 36:1999;5.
2. Spangrude G.J., Smith L., Uchida N.et al. Mouse hematopoietic stem cells. Blood. 78:1991;1395.
3. Geffen D.B., Benharroch D., Yellin A., Ariad S., Or R., Cohen Y. Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation. report of a case with more than 4-year disease-free survival Am J Clin Oncol. 24:2001;566.
4. Sweetenham J.W., Carella A.M., Taghipour G.et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy. results in 175 patients reported to the European Group for Blood and Marrow Transplantation Lymphoma Working Party. J Clin Oncol. 17:1999;3101.
5. Sutherland D.R., Stewart A.K., Keating A. CD34 antigen. molecular features and potential clinical applications Stem Cells. 11(suppl. 3):1993;50.
6. Ikuta K., Weissman I.L. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci U S A. 89:1992;1502.
7. Aihara Y., Buhring H.J., Aihara M., Klein J. An attempt to produce "pre-T" cell hybridomas and to identify their antigens. Eur J Immunol. 16:1986;1391.
8. Krause D.S., Fackler M.J., Civin C.I., May W.S. CD34. structure, biology, and clinical utility Blood. 87:1996;1.
9. Greaves M.F., Brown J., Molgaard H.V.et al. Molecular features of CD34. a hemopoietic progenitor cell-associated molecule Leukemia. 6:1992;31.
10. Simmons P.J., Torok-Storb B. CD34 expression by stromal precursors in normal human adult bone marrow. Blood. 78:1991;2848.
11. To L.B., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood. 89:1997;2233.
12. Berenson R.J., Andrews R.G., Bensinger W.I.et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest. 81:1988;951.
13. Bensinger W.I., Buckner C.D., Shannon-Dorcy K.et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood. 88:1996;4132.
14. Dunbar C.E., Cottler-Fox M., O'Shaughnessy J.A.et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 85:1995;3048.
15. Kohn D.B., Bauer G., Rice C.R.et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood. 94:1999;368.
16. Kohn D.B., Hershfield M.S., Carbonaro D.et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 4:1998;775.
17. Donnelly D.S., Zelterman D., Sharkis S., Krause D.S. Functional activity of murine CD34+ and CD34- hematopoietic stem cell populations. Exp Hematol. 27:1999;788.
18. Gao Z., Fackler M.J., Leung W.et al. Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations. Exp Hematol. 29:2001;910.
19. Bhatia M., Bonnet D., Murdoch B., Gan O.I., Dick J.E. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 4:1998;1038.
20. Sato T., Laver J.H., Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood. 94:1999;2548.
21. Ito T., Tajima F., Ogawa M. Developmental changes of CD34 expression by murine hematopoietic stem cells. Exp Hematol. 28:2000;1269.
22. Tajima F., Sato T., Laver J.H., Ogawa M. CD34 expression by murine hematopoietic stem cells mobilized by granulocyte colony-stimulating factor. Blood. 96:2000;1989.
23. Ogawa M. Changing phenotypes of hematopoietic stem cells. Exp Hematol. 30:2002;3.
24. McNagny K.M., Pettersson I., Rossi F.et al. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol. 138:1997;1395.
25. Sassetti C., Van Zante A., Rosen S.D. Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem. 275:2000;9001.
26. Doyonnas R., Kershaw D.B., Duhme C.et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med. 194:2001;13.
27. Takeda T., Go W.Y., Orlando R.A., Farquhar M.G. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell. 11:2000;3219.
28. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 31:1999;1053.
29. Suzuki A., Andrew D.P., Gonzalo J.A.et al. CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Blood. 87:1996;3550.
30. Tsuji K., Zsebo K.M., Ogawa M. Murine mast cell colony formation supported by IL-3, IL-4, and recombinant rat stem cell factor, ligand for c-kit. J Cell Physiol. 148:1991;362.
31. Sambrook J., Fritsch E.F., Maniatus T. Molecular Cloning. A Laboratory Manual:1989;Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
32. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 132:1983;6.
33. Church G.M., Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A. 81:1984;1991.
34. Brown J., Greaves M.F., Molgaard H.V. The gene encoding the stem cell antigen, CD34, is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblasts. Int Immunol. 3:1991;175.
35. Dugaiczyk A. Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. Biochemistry. 22:1983;1605.
36. Graf T., McNagny K., Brady G., Frampton J. Chicken "erythroid" cells transformed by the gag-myb-ets-encoding E26 leukemia virus are multipotent. Cell. 70:1992;201.
37. Yamaguchi M., Lantz C.S., Oettgen H.C.et al. IgE enhances mouse mast cell Fc(ε)RI expression in vitro and in vivo. evidence for a novel amplification mechanism in IgE-dependent reactions J Exp Med. 185:1997;663.
38. van de Rijn M., Heimfeld S., Spangrude G.J., Weissman I.L. Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci U S A. 86:1989;4634.
39. Osawa M., Hanada K., Hamada H., Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 273:1996;242.
40. Unkeless J.C. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med. 150:1979;580.
41. Karimi K., Redegeld F.A., Heijdra B., Nijkamp F.P. Stem cell factor and interleukin-4 induce murine bone marrow cells to develop into mast cells with connective tissue type characteristics in vitro. Exp Hematol. 27:1999;654.
42. Welker P., Grabbe J., Zuberbier T., Guhl S., Henz B.M. Mast cell and myeloid marker expression during early in vitro mast cell differentiation from human peripheral blood mononuclear cells. J Invest Dermatol. 114:2000;44.
43. Rottem M., Okada T., Goff J.P., Metcalfe D.D. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fcε RI- cell population. Blood. 84:1994;2489.
44. Kirshenbaum A.S., Goff J.P., Semere T., Foster B., Scott L.M., Metcalfe D.D. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 94:1999;2333.
45. Morel F., Szilvassy S.J., Travis M., Chen B., Galy A. Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Blood. 88:1996;3774.
46. Nakamura Y., Ando K., Chargui J.et al. Ex vivo generation of CD34(+) cells from CD34(-) hematopoietic cells. Blood. 94:1999;4053.
47. Krause D.S., Theise N.D., Collector M.I.et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 105:2001;369.
48. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1996;1797.
49. Park I.K., He Y., Lin F.et al. Differential gene expression profiling of adult murine hematopoietic stem cells. Blood. 99:2002;488.
50. Christensen J.L., Weissman I.L. Flk-2 is a marker in hematopoietic stem cell differentiation. a simple method to isolate long-term stem cells Proc Natl Acad Sci U S A. 98:2001;14541.
51. Matthews W., Jordan C.T., Wiegand G.W., Pardoll D., Lemischka I.R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65:1991;1143.
52. Orlic D., Fischer R., Nishikawa S., Nienhuis A.W., Bodine D.M. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood. 82:1993;762.
53. Weissman I.L., Anderson D.J., Gage F. Stem and progenitor cells. origins, phenotypes, lineage commitments, and transdifferentiations Annu Rev Cell Dev Biol. 17:2001;387.
54. Fackler M.J., Krause D.S., Smith O.M., Civin C.I., May W.S. Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells. Blood. 85:1995;3040.
55. Cheng J., Baumhueter S., Cacalano G.et al. Hematopoietic defects in mice lacking the sialomucin CD34. Blood. 87:1996;479.
56. Healy L., May G., Gale Ka Grosveld F., Greaves M., Enver T. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc Natl Acad Sci U S A. 92:1995;12240.
57. Baumhueter S., Singer M., Henzel W.et al. Binding of L-selectin to the vascular sialomucin CD34. Science. 262:1993;436.
58. Hu M.C., Chien S.L. The cytoplasmic domain of stem cell antigen CD34 is essential for cytoadhesion signaling but not sufficient for proliferation signaling. Blood. 91:1998;1152.
59. Delia D., Lampugnani M.G., Resnati M.et al. CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood. 81:1993;1001.
60. Lanza F., Healy L., Sutherland D.R. Structural and functional features of the CD34 antigen. an update J Biol Regul Homeost Agents. 15:2001;1.
61. Fackler M.J., Civin C.I., May W.S. Up-regulation of surface CD34 is associated with protein kinase C-mediated hyperphosphorylation of CD34. J Biol Chem. 267:1992;17540.
62. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 17:1999;255.